What is the current valuation of the Biologic Therapy Market as of 2024?

The Biologic Therapy Market was valued at 308.65 USD Billion in 2024. Read More

What is the projected market valuation for the Biologic Therapy Market in 2035?

The market is projected to reach 450.14 USD Billion by 2035. Read More

What is the expected CAGR for the Biologic Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the Biologic Therapy Market during 2025 - 2035 is 3.49%. Read More

Which segment of the Biologic Therapy Market is expected to have the highest valuation in 2035?

Monoclonal Antibodies are anticipated to reach a valuation of 170.0 USD Billion by 2035. Read More

How do the valuations of different applications in the Biologic Therapy Market compare for 2024?

In 2024, Oncology was valued at 80.0 USD Billion, while Cardiovascular Diseases reached 108.65 USD Billion. Read More

What are the projected valuations for the route of administration segments by 2035?

By 2035, Intravenous administration is expected to reach 170.0 USD Billion. Read More

Which key players are leading the Biologic Therapy Market?

Key players include AbbVie, Amgen, Roche, Johnson & Johnson, and Novartis. Read More

What is the expected growth in the Cell Therapy segment from 2024 to 2035?

The Cell Therapy segment is projected to grow from 60.0 USD Billion in 2024 to 90.0 USD Billion by 2035. Read More

How does the Home Healthcare segment compare to other end-user segments in 2035?

Home Healthcare is expected to reach 170.14 USD Billion, indicating strong growth compared to Clinics and Hospitals. Read More

What is the anticipated valuation for the Vaccines segment by 2035?

The Vaccines segment is projected to reach 110.0 USD Billion by 2035. Read More

Biologic Therapy Market

Biologic Therapy Market Research Report By Therapy Type (Monoclonal Antibodies, Vaccines, Cell Therapy, Gene Therapy), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Intravenous, Subcutaneous, Intramuscular), By End-user (Hospitals, Clinics, Home Healthcare), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.49%

2024 Market Size

$ 308.65 Billion

2035 Market Size

$ 450.14 Billion

Healthcare ● Updated May 2026 Report ID: MRFR/HC/0344-CR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type (USD Billion) | |
  1. 4.1.1 Monoclonal Antibodies | |
  2. 4.1.2 Vaccines | |
  3. 4.1.3 Cell Therapy | |
  4. 4.1.4 Gene Therapy |
2. 4.2 Healthcare, BY Application (USD Billion) | |
  1. 4.2.1 Oncology | |
  2. 4.2.2 Autoimmune Diseases | |
  3. 4.2.3 Infectious Diseases | |
  4. 4.2.4 Cardiovascular Diseases |
3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.3.1 Intravenous | |
  2. 4.3.2 Subcutaneous | |
  3. 4.3.3 Intramuscular |
4. 4.4 Healthcare, BY End-user (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Clinics | |
  3. 4.4.3 Home Healthcare |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Amgen (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Roche (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Johnson & Johnson (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Novartis (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pfizer (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Bristol-Myers Squibb (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Sanofi (FR) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Gilead Sciences (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies | |
  10. 5.2.10 Merck & Co. (US) | | |
    1. 5.2.10.1 Financial Overview | | |
    2. 5.2.10.2 Products Offered | | |
    3. 5.2.10.3 Key Developments | | |
    4. 5.2.10.4 SWOT Analysis | | |
    5. 5.2.10.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE |
7. 6.4 US MARKET ANALYSIS BY APPLICATION |
8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
9. 6.6 US MARKET ANALYSIS BY END-USER |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY APPLICATION |
12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
13. 6.10 CANADA MARKET ANALYSIS BY END-USER |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY APPLICATION |
17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
18. 6.15 GERMANY MARKET ANALYSIS BY END-USER |
19. 6.16 UK MARKET ANALYSIS BY TYPE |
20. 6.17 UK MARKET ANALYSIS BY APPLICATION |
21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
22. 6.19 UK MARKET ANALYSIS BY END-USER |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY APPLICATION |
25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
26. 6.23 FRANCE MARKET ANALYSIS BY END-USER |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY APPLICATION |
29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
30. 6.27 RUSSIA MARKET ANALYSIS BY END-USER |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY APPLICATION |
33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
34. 6.31 ITALY MARKET ANALYSIS BY END-USER |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY APPLICATION |
37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
38. 6.35 SPAIN MARKET ANALYSIS BY END-USER |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END-USER |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY APPLICATION |
46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
47. 6.44 CHINA MARKET ANALYSIS BY END-USER |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY APPLICATION |
50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
51. 6.48 INDIA MARKET ANALYSIS BY END-USER |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY APPLICATION |
54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
55. 6.52 JAPAN MARKET ANALYSIS BY END-USER |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END-USER |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION |
62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
63. 6.60 MALAYSIA MARKET ANALYSIS BY END-USER |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY APPLICATION |
66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
67. 6.64 THAILAND MARKET ANALYSIS BY END-USER |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY APPLICATION |
70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
71. 6.68 INDONESIA MARKET ANALYSIS BY END-USER |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION |
74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
75. 6.72 REST OF APAC MARKET ANALYSIS BY END-USER |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY APPLICATION |
79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
80. 6.77 BRAZIL MARKET ANALYSIS BY END-USER |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY APPLICATION |
83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
84. 6.81 MEXICO MARKET ANALYSIS BY END-USER |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION |
87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
88. 6.85 ARGENTINA MARKET ANALYSIS BY END-USER |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END-USER |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END-USER |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION |
104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
105. 6.102 REST OF MEA MARKET ANALYSIS BY END-USER |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY END-USER, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END-USER, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END-USER, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END-USER, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END-USER, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END-USER, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END-USER, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END-USER, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END-USER, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END-USER, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END-USER, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END-USER, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END-USER, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END-USER, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END-USER, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END-USER, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END-USER, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END-USER, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END-USER, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END-USER, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END-USER, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END-USER, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END-USER, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END-USER, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END-USER, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END-USER, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END-USER, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END-USER, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END-USER, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END-USER, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Biologic Therapy Market Segmentation

Biologic Therapy Market By Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Vaccines
Cell Therapy
Gene Therapy

Biologic Therapy Market By Application (USD Billion, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases
Cardiovascular Diseases

Biologic Therapy Market By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Intramuscular

Biologic Therapy Market By End-user (USD Billion, 2025-2035)

Hospitals
Clinics
Home Biologic Therapy Market

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”